Profile: Oragenics Inc (OGEN.A)
Oragenics, Inc., incorporated on November 6, 1996, develops, markets and sells probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora. The Company is focused on offering antibiotics against infectious disease and on developing treatments for oral mucositis. The Company is engaged in developing its antibiotic product candidate, MU1140, as well as other homolog antibiotic product candidates; researching AG013 in connection with the treatment of Oral Mucositis; commercializing its ProBiora3 probiotic products, and has other product candidates for out licensing or partnering..
MU1140, Homologs of MU1140 and Other Lantibiotics
MU1140 is an antibiotic that is produced by the parent of the SMaRT strain. MU1140 is active against all Gram positive bacteria against which it has been tested, including those responsible for various healthcare-associated infections (HAIs). MU1140 has demonstrated activity against a range of disease-causing Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecalis (VRE), Clostridium difficile (C. difficile.), Mycobacterium tuberculosis and Bacillus anthracis.
ProBiora3 Oral Care Probiotics
ProBiora3 is a blend of three naturally occurring strains of beneficial bacteria, including Streptococcus oralis KJ3, Streptococcus uberis KJ2 and Streptococcus rattus JH145, which supports overall oral health. The Company promotes ProBiora3 as the active ingredient in its consumer branded products, including EvoraPlus, EvoraKids and EvoraPet, and the professional branded product, EvoraPro. EvoraPlus and EvoraKids are flavored probiotic tablets intended for daily use by adults and children, respectively, after brushing their teeth. EvoraPet is for companion pets, such as cats and dogs, and comes in a tasteless and odorless powder form. EvoraPro is a professional strength product designed for the dental office channel. In addition to its house-branded products, the Company also market ProBiora3 as an active ingredient for private label products, as well as in bulk for licensing applications.
Other Product Candidates and Technologies
LPT3-04 is a naturally occurring compound, which is normally consumed in the human diet in small amounts and results in dose-dependent weight loss in experimental animal models. The Company has a licensing arrangement of its LPT3-04 weight-loss product candidate for further development to LPThera LLC. LPThera LLC is responsible for commercializing the products containing LPT3-04 using commercially reasonable efforts.
The Company's SMaRT Replacement Therapy is based on the creation of a genetically modified strain of bacteria that colonizes in the oral cavity and replaces native bacteria that cause tooth decay. The Company's SMaRT Replacement Therapy product candidate is designed to be a painless, one-time, five-minute topical treatment applied to the teeth that has the potential to offer lifelong protection against dental caries or tooth decay. Its SMaRT Replacement Therapy technology is based on the creation of a genetically altered strain of S.mutans, called SMaRT, which does not produce lactic acid.
The Company competes with BioGaia AB/Sunstar and BLIS Technologies, Ltd.
4902 Eisenhower Blvd Ste 125
TAMPA FL 33634-6342
Company Web Links
- BRIEF-Oragenics receives audit opinion with going concern explanation
- BRIEF-Oragenics board authorized to increase authorized shares of stock from 100 mln shares to 250 mln shares
- BRIEF-Oragenics says U.S. FDA grants fast track designation for development of co's AG013 for oral mucositis
- BRIEF-Oragenics - expects to file an investigational new drug (IND) update and initiate a phase 2 study with AG013 in United States and Europe in early 2017